Prellis Biologics, Inc. | January 14, 2022
Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system based on human lymph node organoids. The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins.
Under the terms of the agreement, Prellis and Bristol Myers Squibb will collaborate on the generation of human antibody libraries for select targets. Prellis will receive from Bristol Myers Squibb an undisclosed up-front payment, funding for research activities, development, sales milestones and royalties for licensed antibodies.
"With industry leading speed, the EXIS platform provides high affinity antibodies, derived from lymph node organoids printed with Prellis’ foundational technology, using human PBMCs. We are looking forward to working with Bristol Myers Squibb to demonstrate advantages of in vitro human antibody discovery with the EXIS platform."
Melanie P. Matheu, PhD, Founder and CEO of Prellis Biologics
Kevin Chapman, PhD, CSO of Prellis, added, "The EXIS platform effectively breaks tolerance enabling direct discovery of human antibodies to challenging human antigens in less than two weeks."
Prellis Biologics, Inc. is the first company to develop a fully synthetic, animal-free, functional human immune system, EXIS™. The EXIS platform allows Prellis to harness fully human immune responses for the development of antibody therapeutics, disease models, and target discovery. With industry-leading speed and resolution, Prellis’ proprietary holographic printing technology is able to accurately match and rapidly replicate human organ and tissue structures. Prellis is dedicated to improving patient lives by discovering novel therapeutics, utilizing its unique capabilities in antibody discovery and in vitro human disease models. Prellis Biologics, Inc. was founded in 2016 and is a privately held company based in the San Francisco Bay Area.
Equillium, Inc. | February 17, 2022
Equillium, Inc. a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutics, Inc., a privately held clinical-stage biotechnology company. Bioniz developed its novel structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from its proprietary product discovery platform. The Bioniz lead product candidates are multi-specific inhibitors of key disease-driving, clinically validated cytokine targets aimed at addressing unmet needs across a range of immuno-inflammatory indications.
With the acquisition of Bioniz, Equillium obtained exclusive worldwide rights to all current and future Bioniz products. The transaction consideration is comprised of an all-stock upfront payment of 5,699,492 unregistered shares of common stock of Equillium issuable to Bioniz stockholders, which represents approximately 19.3% of Equillium’s outstanding capital stock. Approximately 97% of the issued Equillium stock is subject to a standard 6-month lock-up provision and thereafter will be released ratably each month over the following 6 months. Equillium is also obligated to pay Bioniz stockholders up to $57.5 million in potential development milestone payments across three Bioniz clinical candidates (BNZ-1, BNZ-2, and BNZ-3) beginning upon first U.S. marketing approval, and up to $250 million in sales milestone payments based upon BNZ-1 achieving calendar year global net sales of $500, $1,000, $1,500, and $2,000 million. Other than the aforementioned milestones, Equillium does not have any third-party obligations with respect to milestones or royalties related to the Bioniz products or platform. Equillium has sole discretion over the timing and extent of advancing clinical development of the Bioniz products. Bioniz was estimated to have modestly positive net working capital at closing.
Webcast and Conference Call
Management will host a conference call accompanied by a slide presentation to discuss the acquisition of Bioniz for analysts and institutional investors, at 8:00 am ET today, February 16, 2022. To access the call, please dial (888) 350-3846 or (646) 960-0251 and, if needed, provide confirmation number 8770084. A live webcast of the call will also be available on the company’s Investor Relations page at https://ir.equilliumbio.com/events-and-presentations. The webcast will be archived for 180 days.
Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited.
Bioniz is a clinical-stage biopharmaceutical company developing precision cytokine targeted therapies for the treatment of immuno-inflammatory diseases. Bioniz’s platform incorporates world class expertise in cytokine biology to advance a novel therapeutic approach to selectively inhibit functionally redundant cytokines while leaving the rest of the cytokine network intact. Bioniz is developing a robust pipeline of product candidates in multiple autoimmune indications.
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
LuminUltra | September 14, 2020
Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be customized for testing facilities throughout North America. LuminUltra's accurate GeneCount® COVID-19 RT-qPCR Testing Solution comprises multiple components that together make up an end-to-end solution, including: sample collection kits; isolation reagents; the COVID-19 Assay; and a range of quick-detection qPCR testing devices with software for simple interpretation of COVID-19 test results in under two hours. With the authorization of the COVID-19 Assay, LuminUltra will be able to offer flexibility to appropriate facilities around the world by providing some or all of the necessary COVID-19 testing components from a single, reputable company. This reduces the need to source components from multiple suppliers, allowing facilities to onboard additional testing capacity quickly. Underscoring its reliable supply chain, LuminUltra responded promptly to the Government of Canada's testing needs earlier in the year, and has been a key supplier of the isolation reagents for the national testing program since April, providing 500,000 tests a week.